Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study
| Autor: | Saskia Gottstein, Daniela Manner, Charis von Auer, Manuela Krause, Katharina Holstein, Ulrich Kalus, Joachim F. Schenk, Andreas Tiede, Rüdiger E. Scharf, Robert Klamroth, Ulrich Geisen, Ralf Ulrich Trappe, Klaus Leimkühler, Peter Neumeister, Jan-Malte Blumtritt, Ute Scholz, Kristina Schilling, Paul Knöbl, Wolfgang Miesbach, Sonja Werwitzke, Angela Huth-Kühne, Armin Koch, Eva Budde, Richard Greil |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
business.industry Immunology Hazard ratio Autoantibody Cell Biology Hematology Odds ratio Biochemistry Gastroenterology Confidence interval Surgery hemic and lymphatic diseases Internal medicine medicine Acquired hemophilia Adverse effect business Survival analysis Cause of death |
| Zdroj: | Blood. 125:1091-1097 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Acquired hemophilia A (AHA) is caused by autoantibodies against factor VIII (FVIII). Immunosuppressive treatment (IST) results in remission of disease in 60% to 80% of patients over a period of days to months. IST is associated with frequent adverse events, including infections as a leading cause of death. Predictors of time to remission could help guide IST intensity but have not been established. We analyzed prognostic factors in 102 prospectively enrolled patients treated with a uniform IST protocol. Partial remission (PR; defined as no active bleeding, FVIII restored >50 IU/dL, hemostatic treatment stopped >24 hours) was achieved by 83% of patients after a median of 31 days (range 7-362). Patients with baseline FVIII |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|